The synthesis of a new analogue of ADP, 2-(p-azidophenyl)-ethylthioadenosine 5'-diphosphate (AzPET-ADP), is described. This compound contains a photolabile phenylazide group attached to the ADP molecule by a thioether link at the purine 2 position. It has been prepared in radioactive form with 32P in the ,f-phosphate at a specific radioactivity of 100 mCi/,umol. The reagent activated platelets, causing shape change and aggregation, with somewhat lower affinity than ADP. On photolysis the affinity was increased. The reagent also inhibited platelet adenylate cyclase stimulation by prostaglandin E1, with considerably higher affi-nity than ADP. On photolysis the affinity was decreased. AzPET-ADP competitively inhibited the binding of 2-methylthio[fl_a2P]ADP, a ligand for the receptor by which ADP causes inhibition of adenylate cyclase. In the dark, AzPET-[_l-32P]ADP bound reversibly and with high affinity to a single population of stes similar in number to the sites that bind
INTRODUCTION
Blood platelets exposed to ADP at micromolar concentrations undergo a change in shape from flat discs to irregular spheres with numerous pseudopodia [1] . In the presence of fibrinogen and Ca2+ ions, they also become sticky and, if stirred, they aggregate [2] [3] [4] . During the aggregation process, arachidonic acid is released from membrane phospholipids by the action of phospholipases A2 and C, and is converted into endoperoxides and thromboxane A2. ADP and serotonin (5-hydroxytryptamine) are released from the platelet dense storage granules, and adhesive proteins and mitogens are released from the a-granules [5] . These processes are regarded as being important contributors to the participation of platelets in the initial phase of wound healing, through the formation of the haemostatic plug, and also for their involvement in thrombotic processes.
From the time of its discovery as an aggregating agent [2, 6] , ADP has been assumed to act through a specific receptor mechanism. Highly negatively charged molecules such as nucleotides are unable to penetrate cell membranes without the intervention of specific transporters, and the concentration of ADP present within the cell is much higher than the extracellular concentration required to provoke the response. The platelet responds specifically to ADP; AMP and other natural nucleoside diphosphates are ineffective, and ATP is a specific and reversible competitive inhibitor [7] . Even On exposure to u.v. light in the presence of platelets, AzPET-[If-32P]ADP was incorporated covalently but non-specifically into several platelet proteins, although prominent intracellular proteins were not labelled. Specific labelling was confined to a single region of SDS/polyacrylamide gels, overlying but not comigrating with actin. Incorporation of radioactivity into this region was inhibited by ADP and by ATP as well as by ADPp8S, ATPaS and pCMBS, but not by adenosine, GDP or AMP. Inhibition of AzPET-[f8-32P]ADP incorporation was closely correlated with inhibition of equilibrium binding of 2-methylthio[fl-32PJADP. These results suggest that the labelled protein, which migrates with an apparent molecular mass of 43 kDa in reduced gels, is the receptor through which ADP inhibits adenylate cyclase.
are a family of derivatives substituted in the 2-position of the adenine nucleus. 2-ChloroADP [8] , 2-azidoADP (2N3-ADP) [9, 10] and 2-methylthioADP (2MeS-ADP) [11, 12] all cause aggregation and shape change with apparent affinities equal to or greater than that of ADP. Like ADP, these analogues also inhibit the response of platelet adenylate cyclase to stimulation by prostaglandins and other agents. This effect is also competitively inhibited by ATP [10, 12, 13] .
Binding sites for 2-substituted ADP derivatives have been identified by equilibrium binding measurements with 2N3-ADP [10] and 2MeS-ADP [12] , both compounds being labelled with 32P in the fl-phosphate. On average, a single platelet has 534 + 44 binding sites for 2MeS-ADP [14] , with a dissociation constant of 5-10 nM, determined by both equilibrium and kinetic measurements [12] . A similar number of binding sites was identified by equilibrium binding of2N2-ADP, with a dissociation constant of 100 nM. Attempts to label this site covalently by photolysing 2N3-ADP in the presence of platelets were unsuccessful [10] . Only non-specific labelling occurred, which was not inhibited by the presence of excess ADP or ATP. We proposed that the analogue, when bound, is oriented in such a way that the nitrene radical generated in the 2-position, where even quite bulky substituents are tolerated, would be unable to contact the binding protein. Photoaffinity labelling of the site might be possible with a reagent in which the nitrene is generated at some distance from the purine ring. We have therefore prepared a reagent of this nature, 2-(p-azidophenyl)-ethylthioadenosine 5'-diphosphate (AzPET-ADP) and describe its use for covalent Synthesis of AzPET-ADP (5) (Scheme 1) AMP was converted into the Nl-oxide with m-chloroperoxybenzoic acid. Ring cleavage with NaOH followed by con-densation with carbon disulphide gave 2-thioAMP (3) [18, 19] . AzPET-ADP was prepared by the condensation of (3) with 1-(2-bromoethyl)-4-azidobenzene (2) followed by phosphorylation of the monophosphate. 2-(4-Nitrophenyl)ethyl bromide was catalytically reduced to the corresponding amine (1) [20] which was diazotized and converted into the azido derivative (2) with NaN3. Condensation of (2) with 2-thioAMP gave the monophosphate (4), the structure of which was confirmed by microanalysis and u.v. and n.m.r. spectra. The monophosphate was converted into the imidazolate and allowed to react with tri-n-butylammonium phosphate [21] . The diphosphate (5) (2) 
RESULTS
As expected, AzPET-ADP proved to be unstable when exposed to u.v. light at 254 nm. The shoulder at 252 nm in the absorption spectrum disappeared after exposure, and was replaced with a trough (Figure 1 ). There was no change in the spectrum on standing for 2 h at room temperature under normal (fluorescent) laboratory lighting. From the rate of disappearance of absorbance at 254 nm, the half-time for photolytic decomposition was estimated at pH 6.4, pH 7.4 and pH 8.4 to be 8.7, 11 and 12.3 s respectively.
AzPET-ADP caused shape change and aggregation when added to human platelets in diluted PRP and in PRP respectively (Figure 2 ). Dose-response relationships obtained with AzPET-ADP and AzPET-ADP after extensive exposure to u.v. light were parallel to those obtained with ADP, indicating that all three compounds have similar intrinsic activities for both effects. The azide was somewhat less potent than ADP (EC50 for ADP/EC50 for AzPET-ADP = 0.1 for shape change and 0.3 for aggregation). The potency after photolysis was increased in each case to a value closer to that of ADP.
AzPET-ADP and its photolytic decomposition product both inhibited the stimulation of platelet adenylate cyclase activity by PGE1, with dose-response curves that were also parallel to that for ADP, and with apparently similar intrinsic activities, when measured in a washed platelet suspension in the presence of EDTA. The azide proved 120-fold more potent in this system than ADP, and the effect of photolysis was to reduce its potency ( Figure 3) .
We measured the binding of AzPET-[fi-32P]ADP to washed human platelets by means of a modification of a previously described technique, replacing the silicone oil barrier with a 20 % sucrose cushion, with a reduction in non-displaceable binding due to trapping of extracellular fluid and an improved recovery of platelets in the pellet. AzPET-ADP bound reversibly to 437 sites on each platelet (Figure 4) . At half-maximal specific binding, which occurred at 10.9 nM ligand, the ratio of specific to nonspecific binding measured in the presence of 0. 8 Competing compounds were present at 0.8 mM.
of dried polyacrylamide slab gels, after electrophoresis in the Laemmli buffer system ( Figure 5 ). The most prominently labelled band ran as an apparent doublet in the 41-45 kDa area, with an appearance reminiscent of a hamburger bun, with the beef corresponding to a lighter zone on the autoradiographs, overlying the prominent Coomassie Blue staining band due to platelet actin. This suggests that the labelled protein is a single band with the same mobility as actin, but not comigrating with it. We therefore refer to this band as a 43 kDa protein. Another prominently labelled band was seen at 68 kDa, probably due to albumin present as a contaminant of the platelet suspension. Labelling of this material was not affected by the presence of competing nucleotides. Several compounds were tested for the ability to inhibit the incorporation of AzPET-ADP into the 43 kDa protein, and the results were compared with those obtained, under nearly identical conditions, with equilibrium binding of 2MeS-ADP. The specific activities of both ligands, which were prepared from the same batch of 32p, were identical (17.5 c.p.m./fmol on the day of counting). The concentration of AzPET-ADP was 0.25 #M and the concentration of 2MeS-ADP was 0.32 ,uM. Competing compounds were included at 0.8 mM. Labelling of the 43 kDa material was blocked by ATP, ADP and p-chloromercuribenzenesulphonate (pCMBS). AMP, adenosine and GDP did not prevent labelling, and 8-bromo-ADP was partly effective. Similar effects of these compounds were seen when equilibrium binding of 2MeS-ADP was measured ( Table 1) .
The four nucleotides that were most effective in blocking incorporation of AzPET-ADP into 43 kDa protein were examined over a range of concentrations from 1 mM to 1 ,sM for the ability to interfere with equilibrium binding of 2MeS-ADP and covalent incorporation ofAzPET-ADP, under closely similar conditions, and with samples of the same platelet suspension. AMP, which had little or no effect, was included as a control. There were small differences between the potencies of these compounds as inhibitors of binding of the two ligands (Figure 6 ), but in general a strong correlation was seen between the two effects. In contrast with the ability of the active compounds to block incorporation of radioactivity into the 43 kDa band, incorporation into the band at 64 kDa was not greatly affected except at the highest concentrations, where some effect of u.v.
absorbance by the nucleotides on the efficiency of photolysis might be expected.
DISCUSSION
Our first attempt to identify a receptor for ADP on blood platelets by photoaffinity labelling using 2N3-ADP [10] was unsuccessful. From the fact that small changes in the ADP molecule at any of several positions can cause a marked loss of affinity, judged by the potency of the analogue as either an agonist or an antagonist [22] , it can be argued that the molecule is held rigidly in its binding site and makes multiple contacts with it. However, at the 2 position, quite bulky substituents, including a spin-labelled radical [18] [18] who found that their nitroxyl spin-labelled ADP analogue was rapidly reduced when bound to platelets, and is supported by the effects of pCMBS. This non-penetrating mercurial thiol reagent inhibits the effect of ADP on adenylate cyclase, and blocks the binding of 2N3-ADP [10] and 2MeS-ADP [12] , although it does not inhibit ADPinduced shape change. This reagent also blocks the equilibrium binding of AzPET-ADP, as well as the covalent incorporation of AzPET-ADP on photolysis ( Figure 5) .
Arguing from the selective effect of pCMBS, we have suggested that the platelet may have two distinct receptors for ADP, one associated with shape change and aggregation and the other with inhibition of adenylate cyclase [12] . However, evidence from the comparison of several competitive inhibitors of both effects of ADP suggests that they are mediated by a single receptor [24] . The possibility that aggregation occurs as a consequence of adenylate cyclase inhibition has been advanced [26] but rejected. There is a wide discrepancy between the potencies of different ADP analogues as aggregating agents and inhibitors of adenylate cyclase [12] , and adenosine analogues that inhibit adenylate cyclase by an effect on the intracellular P site, do not induce aggregation or potentiate other aggregating agents [271. It is possible that a single ADP receptor may cause different actions by interaction with different guanine-nucleotide-binding proteins, as has recently been proposed for the platelet receptor for thrombin [28] .
The binding site associated with the 43 kDa protein is clearly different from the nucleotide-binding sites identified by other investigators. The nucleotide affinity reagent p-fluorosulphonylbenzoyladenosine, which non-competitively inhibits aggregation induced by ADP, labels a 100 kDa protein on the platelet membrane [29] . This reagent does not inhibit the effect of ADP on adenylate cyclase, nor does it block the binding of 2MeS-ADP [30] . However, unlike ATP [7] , it also inhibits aggregation induced by adrenaline and by low concentrations of thrombin, suggesting that its effect is not restricted to interaction with the ADP-binding site. Photoinduced incorporation of ATPaxS labels a site on glycoprotein IIba (120 kDa, reduced) [31] . The relevance of this site to the ADP receptor is questioned by the observation that, in Glanzmann's thrombasthenia, platelet shape change and Ca2+ influx induced by ADP are normal, despite a profound defect in glycoproteins Ilb and Illa [32] .
The procedure used in these experiments for the isolation of platelets, i.e. centrifugation in the cold in the presence of EDTA, leads to a considerable loss in their responsiveness to shape change and aggregation induced by ADP, but to full retention of their sensitivity to the inhibitory effect of ADP on adenylate cyclase. We therefore propose that the protein identified by photoaffinity labelling with AzPET-ADP under these conditions represents the ADP receptor through which ADP inhibits adenylate cyclase.
The discovery ofan efficient mechanism for covalently labelling the platelet receptor identified by 2MeS-ADP binding offers an approach to its purification and characterization. The relevance of this receptor to the physiological function of platelets is supported by the observation that in volunteers given the experimental antithrombotic drug, clopidogrel, which causes marked prolongation of the cutaneous bleeding time and specific inhibition of platelet aggregation by ADP, 2MeS-ADP binding is greatly diminished [14] .
